Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors

NCT03665129 is registered in ClinicalTrials.gov with Innate Pharma as lead sponsor.

NCT NCT03665129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03665129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors
Lead sponsor
Innate Pharma
Phase
Phase 1
Overall status
Terminated
Start date
September 7, 2018
Completion date
February 24, 2021
Enrollment
73 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors